Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer.
Identifieur interne : 000264 ( Main/Exploration ); précédent : 000263; suivant : 000265Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer.
Auteurs : Nicholas R. Mayne [États-Unis] ; Belle K. Lin [États-Unis] ; Alice J. Darling [États-Unis] ; Vignesh Raman [États-Unis] ; Deven C. Patel [États-Unis] ; Douglas Z. Liou [États-Unis] ; Thomas A. D'Amico [États-Unis] ; Chi-Fu Jeffrey Yang [États-Unis]Source :
- Annals of surgery [ 1528-1140 ] ; 2020.
Descripteurs français
- KwdFr :
- Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (chirurgie), Carcinome pulmonaire non à petites cellules (mortalité), Carcinome pulmonaire non à petites cellules (radiothérapie), Délai jusqu'au traitement (MeSH), Facteurs temps (MeSH), Humains (MeSH), Radiochirurgie (MeSH), Stadification tumorale (MeSH), Taux de survie (MeSH), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (chirurgie), Tumeurs du poumon (mortalité), Tumeurs du poumon (radiothérapie), Études de cohortes (MeSH).
- MESH :
- anatomopathologie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- chirurgie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- mortalité : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- radiothérapie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- Délai jusqu'au traitement, Facteurs temps, Humains, Radiochirurgie, Stadification tumorale, Taux de survie, Études de cohortes.
English descriptors
- KwdEn :
- COVID-19 (MeSH), Carcinoma, Non-Small-Cell Lung (mortality), Carcinoma, Non-Small-Cell Lung (pathology), Carcinoma, Non-Small-Cell Lung (radiotherapy), Carcinoma, Non-Small-Cell Lung (surgery), Cohort Studies (MeSH), Humans (MeSH), Lung Neoplasms (mortality), Lung Neoplasms (pathology), Lung Neoplasms (radiotherapy), Lung Neoplasms (surgery), Neoplasm Staging (MeSH), Radiosurgery (MeSH), SARS-CoV-2 (MeSH), Survival Rate (MeSH), Time Factors (MeSH), Time-to-Treatment (MeSH).
- MESH :
- mortality : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- radiotherapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- surgery : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- COVID-19, Cohort Studies, Humans, Neoplasm Staging, Radiosurgery, SARS-CoV-2, Survival Rate, Time Factors, Time-to-Treatment.
Abstract
OBJECTIVE
To evaluate the overall survival of patients with operable stage IA non-small-cell lung cancer (NSCLC) who undergo "early" SBRT (within 0-30 days after diagnosis) versus "delayed" surgery (90-120 days after diagnosis).
SUMMARY OF BACKGROUND DATA
During the COVID-19 pandemic, national guidelines have recommended patients with operable stage IA NSCLC to consider delaying surgery by at least 3 months or, alternatively, to undergo SBRT without delay. It is unknown which strategy is associated with better short- and long-term outcomes.
METHODS
Multivariable Cox proportional hazards modeling and propensity score-matched analysis was used to compare the overall survival of patients with stage IA NSCLC in the National Cancer Data Base from 2004 to 2015 who underwent "early" SBRT (0-30 days after diagnosis) versus that of patients who underwent "delayed" wedge resection (90-120 days after diagnosis).
RESULTS
During the study period, 570 (55%) patients underwent early SBRT and 475 (45%) underwent delayed wedge resection. In multivariable analysis, delayed resection was associated with improved survival [adjusted hazard ratio 0.61; (95% confidence interval (CI): 0.50-0.76)]. Propensity-score matching was used to create 2 groups of 279 patients each who received early SBRT or delayed resection that were well-matched with regard to baseline characteristics. The 5-year survival associated with delayed resection was 53% (95% CI: 45%-61%) which was better than the 5-year survival associated with early SBRT (31% [95% CI: 24%-37%]).
CONCLUSION
In this national analysis, for patients with stage IA NSCLC, extended delay of surgery was associated with improved survival when compared to early treatment with SBRT.
DOI: 10.1097/SLA.0000000000004363
PubMed: 33074904
PubMed Central: PMC7668323
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer.</title><author><name sortKey="Mayne, Nicholas R" sort="Mayne, Nicholas R" uniqKey="Mayne N" first="Nicholas R" last="Mayne">Nicholas R. Mayne</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Surgery, Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Lin, Belle K" sort="Lin, Belle K" uniqKey="Lin B" first="Belle K" last="Lin">Belle K. Lin</name><affiliation wicri:level="2"><nlm:affiliation>University of Arizona College of Medicine-Phoenix, Phoenix, Arizona.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Arizona</region></placeName><wicri:cityArea>University of Arizona College of Medicine-Phoenix, Phoenix</wicri:cityArea></affiliation></author><author><name sortKey="Darling, Alice J" sort="Darling, Alice J" uniqKey="Darling A" first="Alice J" last="Darling">Alice J. Darling</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Surgery, Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Raman, Vignesh" sort="Raman, Vignesh" uniqKey="Raman V" first="Vignesh" last="Raman">Vignesh Raman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Surgery, Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Patel, Deven C" sort="Patel, Deven C" uniqKey="Patel D" first="Deven C" last="Patel">Deven C. Patel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cardiothoracic Surgery, Stanford University, Stanford, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Cardiothoracic Surgery, Stanford University, Stanford</wicri:cityArea></affiliation></author><author><name sortKey="Liou, Douglas Z" sort="Liou, Douglas Z" uniqKey="Liou D" first="Douglas Z" last="Liou">Douglas Z. Liou</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cardiothoracic Surgery, Stanford University, Stanford, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Cardiothoracic Surgery, Stanford University, Stanford</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Stanford Health Care ValleyCare, Pleasanton, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Stanford Health Care ValleyCare, Pleasanton</wicri:cityArea></affiliation></author><author><name sortKey="D Amico, Thomas A" sort="D Amico, Thomas A" uniqKey="D Amico T" first="Thomas A" last="D'Amico">Thomas A. D'Amico</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Surgery, Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Yang, Chi Fu Jeffrey" sort="Yang, Chi Fu Jeffrey" uniqKey="Yang C" first="Chi-Fu Jeffrey" last="Yang">Chi-Fu Jeffrey Yang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, Boston</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33074904</idno><idno type="pmid">33074904</idno><idno type="doi">10.1097/SLA.0000000000004363</idno><idno type="pmc">PMC7668323</idno><idno type="wicri:Area/Main/Corpus">000238</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000238</idno><idno type="wicri:Area/Main/Curation">000238</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000238</idno><idno type="wicri:Area/Main/Exploration">000238</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer.</title><author><name sortKey="Mayne, Nicholas R" sort="Mayne, Nicholas R" uniqKey="Mayne N" first="Nicholas R" last="Mayne">Nicholas R. Mayne</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Surgery, Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Lin, Belle K" sort="Lin, Belle K" uniqKey="Lin B" first="Belle K" last="Lin">Belle K. Lin</name><affiliation wicri:level="2"><nlm:affiliation>University of Arizona College of Medicine-Phoenix, Phoenix, Arizona.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Arizona</region></placeName><wicri:cityArea>University of Arizona College of Medicine-Phoenix, Phoenix</wicri:cityArea></affiliation></author><author><name sortKey="Darling, Alice J" sort="Darling, Alice J" uniqKey="Darling A" first="Alice J" last="Darling">Alice J. Darling</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Surgery, Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Raman, Vignesh" sort="Raman, Vignesh" uniqKey="Raman V" first="Vignesh" last="Raman">Vignesh Raman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Surgery, Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Patel, Deven C" sort="Patel, Deven C" uniqKey="Patel D" first="Deven C" last="Patel">Deven C. Patel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cardiothoracic Surgery, Stanford University, Stanford, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Cardiothoracic Surgery, Stanford University, Stanford</wicri:cityArea></affiliation></author><author><name sortKey="Liou, Douglas Z" sort="Liou, Douglas Z" uniqKey="Liou D" first="Douglas Z" last="Liou">Douglas Z. Liou</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cardiothoracic Surgery, Stanford University, Stanford, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Cardiothoracic Surgery, Stanford University, Stanford</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Stanford Health Care ValleyCare, Pleasanton, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Stanford Health Care ValleyCare, Pleasanton</wicri:cityArea></affiliation></author><author><name sortKey="D Amico, Thomas A" sort="D Amico, Thomas A" uniqKey="D Amico T" first="Thomas A" last="D'Amico">Thomas A. D'Amico</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Surgery, Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Yang, Chi Fu Jeffrey" sort="Yang, Chi Fu Jeffrey" uniqKey="Yang C" first="Chi-Fu Jeffrey" last="Yang">Chi-Fu Jeffrey Yang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, Boston</wicri:cityArea></affiliation></author></analytic><series><title level="j">Annals of surgery</title><idno type="eISSN">1528-1140</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (MeSH)</term><term>Carcinoma, Non-Small-Cell Lung (mortality)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Carcinoma, Non-Small-Cell Lung (radiotherapy)</term><term>Carcinoma, Non-Small-Cell Lung (surgery)</term><term>Cohort Studies (MeSH)</term><term>Humans (MeSH)</term><term>Lung Neoplasms (mortality)</term><term>Lung Neoplasms (pathology)</term><term>Lung Neoplasms (radiotherapy)</term><term>Lung Neoplasms (surgery)</term><term>Neoplasm Staging (MeSH)</term><term>Radiosurgery (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Survival Rate (MeSH)</term><term>Time Factors (MeSH)</term><term>Time-to-Treatment (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (chirurgie)</term><term>Carcinome pulmonaire non à petites cellules (mortalité)</term><term>Carcinome pulmonaire non à petites cellules (radiothérapie)</term><term>Délai jusqu'au traitement (MeSH)</term><term>Facteurs temps (MeSH)</term><term>Humains (MeSH)</term><term>Radiochirurgie (MeSH)</term><term>Stadification tumorale (MeSH)</term><term>Taux de survie (MeSH)</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (chirurgie)</term><term>Tumeurs du poumon (mortalité)</term><term>Tumeurs du poumon (radiothérapie)</term><term>Études de cohortes (MeSH)</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Cohort Studies</term><term>Humans</term><term>Neoplasm Staging</term><term>Radiosurgery</term><term>SARS-CoV-2</term><term>Survival Rate</term><term>Time Factors</term><term>Time-to-Treatment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Délai jusqu'au traitement</term><term>Facteurs temps</term><term>Humains</term><term>Radiochirurgie</term><term>Stadification tumorale</term><term>Taux de survie</term><term>Études de cohortes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To evaluate the overall survival of patients with operable stage IA non-small-cell lung cancer (NSCLC) who undergo "early" SBRT (within 0-30 days after diagnosis) versus "delayed" surgery (90-120 days after diagnosis).</p></div><div type="abstract" xml:lang="en"><p><b>SUMMARY OF BACKGROUND DATA</b></p><p>During the COVID-19 pandemic, national guidelines have recommended patients with operable stage IA NSCLC to consider delaying surgery by at least 3 months or, alternatively, to undergo SBRT without delay. It is unknown which strategy is associated with better short- and long-term outcomes.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Multivariable Cox proportional hazards modeling and propensity score-matched analysis was used to compare the overall survival of patients with stage IA NSCLC in the National Cancer Data Base from 2004 to 2015 who underwent "early" SBRT (0-30 days after diagnosis) versus that of patients who underwent "delayed" wedge resection (90-120 days after diagnosis).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>During the study period, 570 (55%) patients underwent early SBRT and 475 (45%) underwent delayed wedge resection. In multivariable analysis, delayed resection was associated with improved survival [adjusted hazard ratio 0.61; (95% confidence interval (CI): 0.50-0.76)]. Propensity-score matching was used to create 2 groups of 279 patients each who received early SBRT or delayed resection that were well-matched with regard to baseline characteristics. The 5-year survival associated with delayed resection was 53% (95% CI: 45%-61%) which was better than the 5-year survival associated with early SBRT (31% [95% CI: 24%-37%]).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>In this national analysis, for patients with stage IA NSCLC, extended delay of surgery was associated with improved survival when compared to early treatment with SBRT.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33074904</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>272</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>12</Month></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer.</ArticleTitle><Pagination><MedlinePgn>925-929</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0000000000004363</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate the overall survival of patients with operable stage IA non-small-cell lung cancer (NSCLC) who undergo "early" SBRT (within 0-30 days after diagnosis) versus "delayed" surgery (90-120 days after diagnosis).</AbstractText><AbstractText Label="SUMMARY OF BACKGROUND DATA">During the COVID-19 pandemic, national guidelines have recommended patients with operable stage IA NSCLC to consider delaying surgery by at least 3 months or, alternatively, to undergo SBRT without delay. It is unknown which strategy is associated with better short- and long-term outcomes.</AbstractText><AbstractText Label="METHODS">Multivariable Cox proportional hazards modeling and propensity score-matched analysis was used to compare the overall survival of patients with stage IA NSCLC in the National Cancer Data Base from 2004 to 2015 who underwent "early" SBRT (0-30 days after diagnosis) versus that of patients who underwent "delayed" wedge resection (90-120 days after diagnosis).</AbstractText><AbstractText Label="RESULTS">During the study period, 570 (55%) patients underwent early SBRT and 475 (45%) underwent delayed wedge resection. In multivariable analysis, delayed resection was associated with improved survival [adjusted hazard ratio 0.61; (95% confidence interval (CI): 0.50-0.76)]. Propensity-score matching was used to create 2 groups of 279 patients each who received early SBRT or delayed resection that were well-matched with regard to baseline characteristics. The 5-year survival associated with delayed resection was 53% (95% CI: 45%-61%) which was better than the 5-year survival associated with early SBRT (31% [95% CI: 24%-37%]).</AbstractText><AbstractText Label="CONCLUSION">In this national analysis, for patients with stage IA NSCLC, extended delay of surgery was associated with improved survival when compared to early treatment with SBRT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mayne</LastName><ForeName>Nicholas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Belle K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>University of Arizona College of Medicine-Phoenix, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darling</LastName><ForeName>Alice J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Surgery, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Deven C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liou</LastName><ForeName>Douglas Z</ForeName><Initials>DZ</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Health Care ValleyCare, Pleasanton, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amico</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chi-Fu Jeffrey</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="Y">Radiosurgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>19</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33074904</ArticleId><ArticleId IdType="doi">10.1097/SLA.0000000000004363</ArticleId><ArticleId IdType="pmc">PMC7668323</ArticleId><ArticleId IdType="pii">00000658-202012000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382:929–936.</Citation></Reference><Reference><Citation>COVID-19 Dashboard by the Center for Systems Science and Engineering (CSEE) at Johns Hopkins University (JHU). Johns Hopkins University. Available at: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed May 21, 2020.</Citation></Reference><Reference><Citation>Commins J. Surgeon General Urges Providers to ‘Consider Stopping Elective Surgeries.’ Hospitals Push Back. Health Leaders. Available at: https://www.healthleadersmedia.com/clinical-care/surgeon-general-urges-providers-consider-stopping-elective-surgeries-hospitals-push. Accessed May 21, 2020.</Citation></Reference><Reference><Citation>Thoracic Surgery Outcomes Research Network Ig. COVID-19 guidance for triage of operations for thoracic malignancies: a consensus statement from Thoracic Surgery Outcomes Research Network, the Society of Thoracic Surgeons and The American Association for Thoracic Surgery. J Thoracic Cardiovasc Surg 2020; 160:601–605.</Citation></Reference><Reference><Citation>Stahel PF. How to risk-stratify elective surgery during the COVID-19 pandemic? Patient Saf Surg 2020; 14:8.</Citation></Reference><Reference><Citation>Iacobucci G. Covid-19: all non-urgent elective surgery is suspended for at least three months in England. BMJ 2020; 368:m1106.</Citation></Reference><Reference><Citation>Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw 2020; 1:1–4.</Citation></Reference><Reference><Citation>Karen Weise MB, Nicholas BB. The Coronavirus Is Forcing Hospitals to Cancel Surgeries. New York City, NY: New York Times; 2020.</Citation></Reference><Reference><Citation>Guckenberger M, Belka C, Bezjak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement. Radiother Oncol 2020; 146:223–229.</Citation></Reference><Reference><Citation>Raghavan D, Chai SJ, Plate K, et al. Levine cancer institute approach to pandemic care of cancer patients. J Clin Oncol Oncol Pract 2020; 16:299–304.</Citation></Reference><Reference><Citation>National Comprehens. Short-Term Recommendations for Non-Small Cell Lung Cancer Management During the COVID-19 Pandemic (Version 1. 2020). National Comprehensive Cancer Network. Available at: https://www.nccn.org/covid-19/pdf/COVID_NSCLC.pdf. Accessed May 21, 2020.</Citation></Reference><Reference><Citation>COVID-19: Elective Case Triage Guidelines for Surgical Care. Thoracic Cancer Surgery. American College of Surgeons. Available at: https://www.facs.org/-/media/files/covid19/guidance_for_triage_of_nonemergent_surgical_procedures_thoracic_cancer.ashx. Accessed May 21, 2020.</Citation></Reference><Reference><Citation>Mazzone PJ, Gould MK, Arenberg DA, et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest 2020; 158:406–415.</Citation></Reference><Reference><Citation>Banna G, Curioni-Fontecedro A, Friedlaender A, et al. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open 2020; 5:1–3.</Citation></Reference><Reference><Citation>ESMO Management and Treatment Adapted Recommendations in the COVID-19 ERA: Lung Cancer. European Society for Medical Oncology. Available at: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/lung-cancer-in-the-covid-19-era. Accessed May 20, 2020.</Citation></Reference><Reference><Citation>Bilimoria KY, Stewart AK, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008; 15:683–690.</Citation></Reference><Reference><Citation>Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest 2017; 151:193–203.</Citation></Reference><Reference><Citation>The Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. Thorax 1998; 53: (Suppl 1): S1–S8.</Citation></Reference><Reference><Citation>Devbhandari MP, Bittar MN, Quennell P, et al. Are we achieving the current waiting time targets in lung cancer treatment? Result of a prospective study from a large United Kingdom teaching hospital. J Thorac Oncol 2007; 2:590–592.</Citation></Reference><Reference><Citation>Yerokun BA, Yang CJ, Gulack BC, et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg 2017; 154:675–86.e4.</Citation></Reference><Reference><Citation>Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244–285.</Citation></Reference><Reference><Citation>Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010; 134:1628–1638.</Citation></Reference><Reference><Citation>Austin PC. An Introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46:399–424.</Citation></Reference><Reference><Citation>Tian S, Higgins KA, Curran WJ, et al. Stereotactic body radiation therapy vs. surgery in early-stage non-small cell lung cancer: lessons learned, current recommendations, future directions. J Thorac Dis 2018; 10:1201–1204.</Citation></Reference><Reference><Citation>Yerokun BA, Yang C-FJ, Gulack BC, et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer. J Thorac Cardiovasc Surg 2017; 154:675–86.e4.</Citation></Reference><Reference><Citation>Ackerson BG, Tong BC, Hong JC, et al. Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC. Lung Cancer 2018; 125:185–191.</Citation></Reference><Reference><Citation>Albano D, Bilfinger T, Nemesure B. 1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT. Lung Cancer (Auckl) 2018; 9:65–71.</Citation></Reference><Reference><Citation>Chi A, Fang W, Sun Y, et al. Comparison of long-term survival of patients with early-stage non-small cell lung cancer after surgery vs stereotactic body radiotherapy. JAMA Netw Open 2019; 2:e1915724.</Citation></Reference><Reference><Citation>Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 83:348–353.</Citation></Reference><Reference><Citation>Lin Q, Sun X, Zhou N, et al. Outcomes of stereotactic body radiotherapy versus lobectomy for stage I non-small cell lung cancer: a propensity score matching analysis. BMC Pulm Med 2019; 19:98.</Citation></Reference><Reference><Citation>Mokhles S, Verstegen N, Maat AP, et al. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer 2015; 87:283–289.</Citation></Reference><Reference><Citation>Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2011; 81:1352–1358.</Citation></Reference><Reference><Citation>Ostheimer C, Evers C, Palm F, et al. Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer: a population-based study on recent developments. J Cancer Res Clin Oncol 2019; 145:2813–2822.</Citation></Reference><Reference><Citation>Shirvani SM, Jiang J, Chang JY, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 2014; 149:1244–1253.</Citation></Reference><Reference><Citation>Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol 2013; 24:1543–1548.</Citation></Reference><Reference><Citation>Zheng X, Schipper M, Kidwell K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 2014; 90:603–611.</Citation></Reference><Reference><Citation>National Library of Medicine (U.S.). (2016-present). Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy (VALOR). Identifier: NCT02984761. Available at: https://clinicaltrials.gov/ct2/show/NCT02984761. Accessed May 20, 2020.</Citation></Reference><Reference><Citation>National Library of Medicine (U.S.). (2015-present). SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer. Identifier: NCT02562027. Available at: https://clinicaltrials.gov/ct2/show/NCT02562027. Accessed May 20, 2020.</Citation></Reference><Reference><Citation>National Library of Medicine (U.S.). (2020). JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer (STABLE-MATES). Identifier: NCT02468024. Available at https://clinicaltrials.gov/ct2/show/NCT02468024. Accessed May 20, 2020.</Citation></Reference><Reference><Citation>National Library of Medicine (U.S.). (2019). Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC (POSTILV). Identifier: NCT01753414. Available at: https://clinicaltrials.gov/ct2/show/NCT01753414. Accessed May 20, 2020.</Citation></Reference><Reference><Citation>Poullis M. Treatment outcomes in stage I lung cancer: a comparison of surgery and stereotactic body radiation therapy. J Thorac Oncol 2016; 11:e64–e65.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li><li>Californie</li><li>Caroline du Nord</li><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Mayne, Nicholas R" sort="Mayne, Nicholas R" uniqKey="Mayne N" first="Nicholas R" last="Mayne">Nicholas R. Mayne</name></region><name sortKey="D Amico, Thomas A" sort="D Amico, Thomas A" uniqKey="D Amico T" first="Thomas A" last="D'Amico">Thomas A. D'Amico</name><name sortKey="Darling, Alice J" sort="Darling, Alice J" uniqKey="Darling A" first="Alice J" last="Darling">Alice J. Darling</name><name sortKey="Lin, Belle K" sort="Lin, Belle K" uniqKey="Lin B" first="Belle K" last="Lin">Belle K. Lin</name><name sortKey="Liou, Douglas Z" sort="Liou, Douglas Z" uniqKey="Liou D" first="Douglas Z" last="Liou">Douglas Z. Liou</name><name sortKey="Liou, Douglas Z" sort="Liou, Douglas Z" uniqKey="Liou D" first="Douglas Z" last="Liou">Douglas Z. Liou</name><name sortKey="Patel, Deven C" sort="Patel, Deven C" uniqKey="Patel D" first="Deven C" last="Patel">Deven C. Patel</name><name sortKey="Raman, Vignesh" sort="Raman, Vignesh" uniqKey="Raman V" first="Vignesh" last="Raman">Vignesh Raman</name><name sortKey="Yang, Chi Fu Jeffrey" sort="Yang, Chi Fu Jeffrey" uniqKey="Yang C" first="Chi-Fu Jeffrey" last="Yang">Chi-Fu Jeffrey Yang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000264 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000264 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33074904
|texte= Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33074904" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |